公开(公告)号：US20170360783A1

公开(公告)日：2017-12-21

申请号：US15693963

申请日：2017-09-01

Applicant: AbbVie Inc.

Inventor： Christine Collins ,  Emily O. Dumas ,  Bo Fu ,  Abhishek Gulati ,  Yiran Bonnie Hu ,  Jens Kort ,  Matthew Kosloski ,  Preethi Krishnan ,  Yang Lei ,  Chih-Wei Lin ,  Ran Liu ,  Federico Mensa ,  Iok Chan Ng ,  Tami Pilot-Matias ,  David Pugatch ,  Susan Rhee ,  Nancy S. Shulman ,  Roger Trinh ,  Rolado M. Viani ,  Stanley Wang ,  Zhenzhen Zhang

IPC: A61K31/4985 ,  A61K31/454

CPC classification number: A61K31/4985 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.